The role of pacritinib in the management of myelofibrosis

Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis

(2013) Daniel J. DeAngelo et al.   BRITISH JOURNAL OF HAEMATOLOGY

A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)

(2013) John Mascarenhas et al.   BRITISH JOURNAL OF HAEMATOLOGY

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

(2013) A Pardanani et al.   LEUKEMIA

JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary Myelofibrosis

(2013) Giovanni Barosi et al.   PLoS One

FLT3-ITD Knockin Impairs Hematopoietic Stem Cell Quiescence/Homeostasis, Leading to Myeloproliferative Neoplasm

(2012) S. Haihua Chu et al.   Cell Stem Cell

Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

(2012) Oliver Weigert et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML

(2012) V Novotny-Diermayr et al.   Blood Cancer Journal

Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms

(2011) S. Anand et al.   BLOOD

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

(2011) Animesh Pardanani et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma

(2011) Anthony D. William et al.   JOURNAL OF MEDICINAL CHEMISTRY

Macrocycles Are Great Cycles: Applications, Opportunities, and Challenges of Synthetic Macrocycles in Drug Discovery

(2011) Eric Marsault et al.   JOURNAL OF MEDICINAL CHEMISTRY

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

(2011) S Hart et al.   LEUKEMIA

Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis

(2011) Ayalew Tefferi et al.   MAYO CLINIC PROCEEDINGS

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia

(2011) S Hart et al.   Blood Cancer Journal

The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma

(2011) E Derenzini et al.   Blood Cancer Journal

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease

(2010) H. Akada et al.   BLOOD

Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis

(2010) H. Alchalby et al.   BLOOD

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

(2009) P. Guglielmelli et al.   BLOOD

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells

(2009) Y. Wang et al.   BLOOD

Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model

(2008) L. Li et al.   BLOOD

Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders

(2008) F Cervantes et al.   LEUKEMIA

The exploration of macrocycles for drug discovery — an underexploited structural class

(2008) Edward M. Driggers et al.   NATURE REVIEWS DRUG DISCOVERY